There is evidence from RCTs that rtCGM reduces HbA1c and increases TIR in people with type 2 diabetes treated with multiple daily injections [27] or basal insulin [9], and is more effective than SMBG in minimizing hypoglycemia for people using therapies at high hypoglycemic risk [28]. This evidence concerns the gene INS and type 2 diabetes mellitus.